There is a large unmet market need for big data solutions in healthcare. However, is there a funding gap between the medical VCs and traditional technology investors?
In order to invest in big data HealthTech startups, investors need to have dual expertise in healthcare and technologies. They need to understand both the uniqueness and defensibility of the company’s data-related technologies, understand where the solution creates value in the complex healthcare ecosystem—and know how to prove it to the potential buyers and users!
This panel will discuss the following: Who are the players that have this knowledge and are investing in big data HealthTech startups? What are the major milestones HealthTech companies needs to accomplish before they are fundable by venture capitalists? How do they get initial funding to show proof of concept? What are investors looking for in seed, series A, and series B milestones? What are the challenges in the revenue models? What are the market adoption risk? Are there proven roadmap in the big data HealthTech emerging area?
Anne DeGheest is managing partner at MedStars Ventures Partners. Since 1986, she has been a mentor capitalist specializing in investing and mentoring early-stage start-ups in healthcare. The life science companies for which she has been a founder or an early advisor have generated over $6 billion in market capitalization. She provided angel capital, hands-on operating expertise and/or business strategy in the founding of major companies like Pyxis (CareFusion), Aspect Medical (acquired by Covidien), VISX (acquired by AMO), Thermage (merged into Solta Medical), VISICU(acquired by Philips), Masimo (Nasdaq: MASI). She also helped grow new entrepreneurial division of large corporations like Johnson & Johnson, Baxter, Medtronic and McKesson. She was also part of the founding executive team of Nellcor (a division of Covidien), MedPool and OmniCell (Nasdaq: OMCL).
Anne founded in 2010 HealthTech Capital, a group of private investors dedicated to funding and mentoring new “HealthTech” start ups to decrease healthcare cost and empower patients. HealthTech capital is an ecosystem of angels, venture capitalists, providers and industry key players with the three sets of expertise needed to succeed in this new HealthTech space: healthcare, technology and user engagement.
She is a faculty guest speaker at Stanford Business School, Dartmouth Tuck and Singularity University. She is an early investor, board member, observer or advisor to Pixel Optics, CareinSync Visioneering and other early stage medical devices. She is an Entrepreneur-In-Residence with Canaan Partners. She started her career at Raychem after receiving a MBA from Harvard and an Master in Business Engineering from University of Brussels.
Alexis Borisy is a successful biotechnology entrepreneur with more than 20 years of experience building and operating innovative science-based organizations. Mr. Borisy joined the life sciences venture capital firm Third Rock Ventures in 2009 to focus on the formation of new companies. He co-founded Foundation Medicine and served as the company’s first CEO and currently as its Chairman, co-founded Blueprint Medicines, and launched and is serving as interim CEO of Warp Drive Bio. Prior to joining Third Rock Ventures, Mr. Borisy founded CombinatoRx in 2000, serving as its Chief Executive Officer and bringing the company public on the NASDAQ. He has raised more than $1b in financing and business development deals, and has authored numerous scientific papers and patents.
Mr. Borisy was honored as the Massachusetts Institute of Technology’s Technology Review Innovator of the Year, was chosen as the New England Entrepreneur of the Year in Life Sciences, and was honored as a Presidential Scholar. Mr. Borisy’s undergraduate degree in chemistry is from the University of Chicago, and he did his graduate work at Harvard University.
Bryan joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock’s Palo Alto office and focuses on a broad range of healthcare investments. Bryan is currently Chairman of the Board of Directors of Achaogen, Castlight Health, and Ironwood Pharmaceuticals (NASDAQ: IRWD), in addition to serving on the Board of several other private and public companies. Past investments include athenahealth (NASDAQ: ATHN), Illumina (NASDAQ: ILMN) and Sirna Therapeutics (acquired by Merck). Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006 and has been the highest-ranking healthcare investor on Forbes’ Midas List since 2008.
Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College.
Tom co-leads Cambia’s venture investing effort and focuses on solutions that will lower cost, improve access, and broadly help transform the sustainability of our health care system. He also helps manage Cambia portfolio of internally developed and acquired operating companies. Prior to accepting this role at Cambia, Tom was a partner at Advanced Technology Ventures, where he lead ATV’s efforts in Healthcare technology. He represented ATV on the boards of several portfolio companies including Aperio (acquired by Danaher: DHR), Helixis (acquired by Illumina: ILMN), Valeritas, PolyRemedy, Gynesonics, Zeltiq Aesthetics (NSDQ: ZLTQ) and Solar Junction. Prior to joining ATV, Tom had significant operating experience in the health care industry including various strategy, business development, sales, and marketing roles at leading technology companies. Most recently he served as VP of corporate strategy and business development at McKesson Corporation, one of the primary players in the healthcare IT and services industry. Prior to McKesson, he managed sales and healthcare strategy while earning his entrepreneurial stripes and wounds at FitLinxx, a venture-backed startup that pioneered the fitness and activity monitoring market including the technology behind the Nike+ system. Before that Tom was a Product Manager at Genentech and was responsible for the successful Nutropin™, Nutropin AQ™ and Pulmozyme™ franchises and he started his career as a consultant with The Wilkerson Group. Tom holds an M.B.A. from the Wharton School, a B.A. from the University of Pennsylvania and was an All American rugby player. He also sheepishly admits he was once the New Hampshire State high school math champion.
For information on exhibition and sponsorship opportunities at the conference, contact Sharon Pierce at (203) 304-9476 or email@example.com
For information on trade opportunities with O'Reilly conferences contact mediapartners
For media-related inquiries, contact Maureen Jennings at firstname.lastname@example.org
View a complete list of Strata Rx contacts